BioAge在诺和诺德ZEUS试验失败引发暴跌后反弹19%

Shares of BioAge Labs (BIOA), a clinical-stage biopharmaceutical company focused on metabolic diseases, rose 19% on Monday. This allowed the stock to stage a partial recovery after it plunged 64% on Friday, triggered by Novo Nordisk's high-profile trial failure.
{"type": "symbol-chart", "props": {"ticker": "BIOA"}, "data": [{"symbol": {"id": 780028, "slug": "bioa", "name": "BIOA", "company": "BioAge Labs, Inc.", "company_name": "BioAge Labs, Inc.", "equity_type": "stocks", "fund_type_id": 0, "followers_count": 1544, "div_yield_type": "forward", "index_group": null, "is_bdc": false, "is_reit": false, "is_currency": false, "is_crypto": false, "is_mutual_funds": false, "is_etf": false, "is_cef": false, "is_index": false, "is_bond": false, "is_commodity": false}, "prices": {"id": 780028, "last": 10.74, "change": 1.700000000000001, "percent_change": 18.8053, "last_time": "2026-08-03T15:58:58.000-04:00", "high": 10.95, "low": 9.19, "open": 9.49, "prev_close": 9.04, "volume": 2865356.152911}, "ratings": {"quant_rating": 2.733275563258232, "sell_side_rating": 4.33333, "authors_rating": 3.0}, "key_data": {"div_rate_fwd": null, "div_rate_ttm": null, "div_yield_fwd": null, "dividend_yield": null, "short_interest_shares_outstanding": 5.513944316675775, "marketcap": 401852700.0, "impliedmarketcap": null, "estimate_eps": -2.50781, "diluted_eps_excl_extra_itmes": -2.392358, "estimate_ffo": null, "ffo_per_share_diluted": null, "pe_ratio_fwd": -3.60473879600129, "last_close_price_earnings_ratio": null}}]}
Monday's followed the wreckage of July 31, when BioAge shares plunged almost 64% after Novo Nordisk (NVO) disclosed that its anti-inflammatory drug ziltivekimab failed to reduce major adverse cardiovascular events in its Phase 3 ZEUS trial. Because BioAge's lead candidate, BGE-102, targets the same underlying inflammation pathway via NLRP3 inhibition, sitting upstream of the IL-6 mechanism Novo's drug targeted, the market treated Novo's failure as a direct read-through risk to BioAge's cardiometabolic program.
The sell-off swept across inflammation-focused biotechs, hitting peers including Monte Rosa Therapeutics (GLUE), Neurocrine Biosciences (NBIX), and Neumora Therapeutics (NMRA) alongside BIOA.
Today's recovery followed one of the sharpest single-session declines in the stock's recent history. The table below shows BIOA's daily returns over the past several sessions, illustrating the severity of the July 31 drawdown and the partial rebound today.
{"type": "table", "props": {"data": [{"date": "Aug 3, 2026", "return": "+18.81%"}, {"date": "Jul 31, 2026", "return": "-63.62%"}, {"date": "Jul 30, 2026", "return": "+11.99%"}, {"date": "Jul 29, 2026", "return": "+1.23%"}, {"date": "Jul 28, 2026", "return": "+4.98%"}, {"date": "Jul 27, 2026", "return": "-4.09%"}, {"date": "Jul 24, 2026", "return": "-0.59%"}, {"date": "Jul 23, 2026", "return": "-0.18%"}, {"date": "Jul 22, 2026", "return": "-3.13%"}, {"date": "Jul 21, 2026", "return": "+1.48%"}, {"date": "Jul 20, 2026", "return": "-2.15%"}], "columns": [{"header": "Date", "accessor": "date", "align": "left"}, {"header": "Daily Return", "accessor": "return", "align": "right", "component": {"type": "signed-value"}}], "title": "BIOA Daily Returns"}}
Stephen Ayers rated BIOA a "Hold" on January 16, noting the stock's prior rally was driven by BGE-102's Phase 1 data and Eli Lilly's acquisition of a competing NLRP3 program, while cautioning that the drug's brain-penetrant design raises safety questions and that near-term value hinges entirely on unproven Phase 2a efficacy and safety data; the company held approximately $296 million in cash with roughly four years of runway at the time of writing. Read more
Seeking Alpha community members were sharply divided on the sell-off, with sentiment ranging from outright bullish contrarianism to deep skepticism about the underlying biology and trial methodology.